Regulatory function of CD4+CD25++ T cells in patients with myasthenia gravis is associated with phenotypic changes and STAT5 signaling: 1,25-Dihydroxyvitamin D3 modulates the suppressor activity.


Alahgholi-Hajibehzad M., Oflazer P., Aysal F., Durmus H. , Gulsen-Parman Y. , MARX A., ...More

Journal of neuroimmunology, vol.281, pp.51-60, 2015 (Journal Indexed in SCI Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 281
  • Publication Date: 2015
  • Doi Number: 10.1016/j.jneuroim.2015.03.008
  • Title of Journal : Journal of neuroimmunology
  • Page Numbers: pp.51-60

Abstract

Regulatory T cells were investigated in early-onset (EO) and late-onset (LO) myasthenia gravis patients with anti-acetylcholine receptor antibody (AChR-MG). Alterations in PD-1 and PD-L1 on CD4(+)CD25(++) (Treg) and responder T cells (Tresp, CD4(+)CD25(-)) were observed in LOMG patients. GITR was decreased on CD4(+)CD25(++) of all patients. Decrease of FOXP3 was associated with lower phosphorylation of STAT5.1,25-dihydroxyvitamin D3 (VitD3) increased suppression in co-culture with a stronger effect in patients by acting possibly both on cell groups. Changes in surface molecules and intracellular pathways contribute to the defects of Treg in non-thymomatous AChR-MG and VitD3 can have modulatory effects. (C) 2015 Elsevier B.V. All rights reserved.